DBV Technologies is a global clinical stage biopharmaceutical company developing a novel class of immunotherapy against food allergies. Their investigational treatment portfolio is built over Viaskin® platform, a novel technology constituted of an electrostatic patch that activates the immune system through the skin. A family of treatments is being developed over such platform, of which the treatment against peanut allergies « Viaskin® Peanut » is the most advanced programme.
While DBV Technologies was progressively accumulating data from Phase II and III clinical studies over Viaskin® Peanut, they asked DNAlytics to elaborate dedicated models capable of monitoring the patient reaction to the treatment, and of predicting the treatment outcome.
DNAlytics team processed patient data (treated + placebo-controlled individuals), including epidemiological and demographic data, treatment doses, as well as various generic and peanut-specific protein markers from blood-based follow-up. DNAlytics results helped in understanding the treatment progression and proposed promising approaches to potentially assist with assessing the efficacy of Viaskin® Peanut. Additional studies are ongoing to understand whether a particular combination of some measured quantities could potentially act as reliable biomarkers for understanding patient response.
Evolution over time of the predicted peanut tolerance
for children treated with Viaskin® Peanut 250μg
within VIPES and OLFUS-VIPES studies.
Reference : A. Peillon et al.,
ACAAI Poster presentation, 2016.
"It has been wonderful to work with DNAlytics ! Their level of responsiveness, understanding, adaptability and professionalism have been outstanding."
Todd Green, MD
Vice President, Medical Affairs North America
You want to get insight in the data from your clinical studies?